If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-17. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
==== Congenital ==== A persistent thyroglossal duct is the most common clinically significant birth defect of the thyroid gland. A persistent sinus tract may remain as a vestigial remnant of the tubular development of the thyroid gland. Parts of this tube may be obliterated, leaving small segments to form thyroglossal cysts. Preterm neonates are at risk of hypothyroidism as their thyroid glands are insufficiently developed to meet their postnatal needs. In order to detect hypothyroidism in newborn babies, to prevent growth and development abnormalities in later life, many countries have newborn screening programs at birth. Infants with thyroid hormone deficiency (congenital hypothyroidism) can manifest problems of physical growth and development as well as brain development, termed cretinism. Children with congenital hypothyroidism are treated supplementally with levothyroxine, which facilitates normal growth and development. Mucinous, clear secretions may collect within these cysts to form either spherical masses or fusiform swellings, rarely larger than 2 to 3 cm in diameter. These are present in the midline of the neck anterior to the trachea. Segments of the duct and cysts that occur high in the neck are lined by stratified squamous epithelium, which is essentially identical to that covering the posterior portion of the tongue in the region of the foramen cecum. The disorders that occur in the lower neck more proximal to the thyroid gland are lined by epithelium resembling the thyroidal acinar epithelium.
==== Education ==== The educational field also was a major way for adopting Western-style music. The educational reforms were led by Isawa Shūji (1851–1917) and Luther Whiting Mason (1828–1896). In 1880, the Music Research Institute in Tokyo (Ongaku Torishirabe Gakari), headed by Izawa Shuji, was founded. The Institute had three main tasks: 1) to introduce compulsory music teaching in schools, to introduce Western-style songs; 2) to train music teachers for the further development of professional musical activities; 3) to create music score collections for children, in which Japanese and Western style music elements could be combined. Thus, the first music scores "The First Collection for Primary School" was published in 1881. The newly educated music teachers organized lessons in singing, music theory, playing musical instruments (koto, kokyū, piano, organ and violin). In 1887, the Music Research Institute was reformed into Tokyo Academy of Music, which gave the Institution a new status and contributed to its further development. Western music was regarded as an essential contributory factor for modernization. The new curriculum was improved, and the number and quality of the musical events increased. Tokyo Academy of Music became the first Western-style music educational establishment in Japan. This was the nascence of schools teaching composition in the Western style in Japan, the genesis of an opera tradition in Japan, and laid the foundations for the Japanese formal tradition of familiarization with Western music.
The life cycle of this insect has four stages: fertilized egg, larva, pupa, and adult. Embryogenesis in Drosophila has been extensively studied, as its small size, short generation time, and large brood size makes it ideal for genetic studies. It is also unique among model organisms in that cleavage occurs in a syncytium.
Sources: en.wikipedia.org
=== Critical response === On Rotten Tomatoes, the first season has an approval rating of 89% based on 38 reviews, with an average rating of 7.61/10. The website's critical consensus reads: "A stellar series perfect for anyone looking for a little hope, Stargirl is delightful fun the whole family can enjoy". On Metacritic it has a weighted average score of 68 out of 100 based on 8 reviews, indicating "generally favorable reviews". Brian Lowry of CNN described the series as "hardly seeks to reinvent the wheel, or even expand the mold. Still, its mix of solid characters, clever writing and youthful exuberance casts a brighter light than most". Daniel Fienberg of The Hollywood Reporter gave a review, calling it "derivative, but should fill the superhero-origin-story-shaped hole in your heart" and wrote: "The result is that a show that is frequently derivative to the point of distraction might actually fill a need for viewers able to concentrate on its occasional charms until better superhero shows return". On Rotten Tomatoes, the second season holds an approval rating of 100% based on 5 reviews, with an average rating of 8.2/10.
=== Phenolics === E. globulus bark contains quinic, dihydroxyphenylacetic and caffeic acids, bis(hexahydroxydiphenoyl (HHDP))-glucose, galloyl-bis(HHDP)-glucose, galloyl-HHDP-glucose, isorhamentin-hexoside, quercetin-hexoside, methylellagic acid (EA)-pentose conjugate, myricetin-rhamnoside, isorhamnetin-rhamnoside, mearnsetin, phloridzin, mearnsetin-hexoside, luteolin and a proanthocyanidin B-type dimer, digalloylglucose and catechin. The hydrolyzable tannins tellimagrandin I, eucalbanin C, 2-O-digalloyl-1,3,4-tri-O-galloyl-β-D-glucose, 6-O-digalloyl-1,2,3-tri-O-galloyl-β-D-glucose, as well as gallic acid and (+)-catechin can also be isolated. Tricetin is a rare flavone aglycone found in the pollen of members of the Myrtaceae, subfamily Leptospermoideae, such as E. globulus.
Stupor: absence of psycho-motor activity; not actively relating to the environment Catalepsy: passive induction of a posture held against gravity Waxy flexibility: maintaining positions imposed by the examiner Mutism: minimal or absent verbal response (not due to aphasia) Negativism: resistance or lack of response to instructions or external stimuli Posturing: spontaneous and active maintenance of a posture against gravity Mannerisms: odd or exaggerated caricatures of normal actions Stereotypy: repetitive, abnormally frequent, non-goal-directed movements Agitation: excessive activity not influenced by external stimuli Grimacing: sustained facial expression Echolalia: mimicking another's speech Echopraxia: mimicking another's movements Other disorders (additional code 293.89 [F06.1] to indicate the presence of the co-morbid catatonia):
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.